相关实验视频
Updated: Jun 29, 2025

12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
18.8K
估计糖尿病药物的可持续性成本价格
Melissa J Barber1,2,3, Dzintars Gotham4,5, Helen Bygrave5
1Yale Collaboration for Regulatory Rigor, Integrity, and Transparency (CRRIT), New Haven, Connecticut.
JAMA network open
|March 27, 2024
概括
胰岛素,SGLT2Is和GLP1As等糖尿病药物的制造成本明显低于市场价格. 增加仿制药和生物类似药的竞争可能会使这些重要的治疗方法在全球范围内更容易获得.
科学领域:
- 药物经济学 药物经济学
- 全球健康 全球健康
- 制药价格的制定 制药价格的制定
背景情况:
- 糖尿病的全球负担正在增加,给医疗保健系统和患者带来了巨大的财务压力,特别是在低收入和中等收入国家.
- 基本糖尿病药物的可获得性受到其市场价格的严重影响,但制造成本和这些价格之间的关系仍然不太清楚.
研究的目的:
- 估计胰岛素的制造成本,-葡萄糖共运输体2抑制剂 (SGLT2Is) 和类似葡萄糖的1激动剂 (GLP1As).
- 为这些糖尿病药物确定可持续的基于成本的价格.
- 将衍生CBP与它们在全球不同地区的当前市场价格进行比较.
主要方法:
- 进行了经济评估,模拟了胰岛素,SGLT2Is和GLP1As的制造成本.
- 活性药物成分成本与配方,运营费用和利率相结合,以估计CBP.
- 根据2023年1月的数据,CBP与来自13个代表不同收入水平的国家的市场价格进行了比较.
主要成果:
- 估计每年胰岛素治疗的CBPs从每名患者50美元到111美元不等,取决于类型和治疗方案.
- 对于SGLT2抑制剂的月度CBP在1.30美元至3.45美元之间 (除了例外),对于GLP1激动剂,它们的价格从0.75美元到72.49美元不等.
- 计算的CBP价格远低于被调查国家的市场价格.
结论:
- 现代糖尿病药物的高价格阻碍了世界各地许多国家的患者获得治疗.
- 该研究表明,促进强有力的仿制药和生物类似药竞争可以显著降低药品价格.
- 这种竞争对于实现更实惠的糖尿病治疗选择和在全球范围内扩大治疗机会至关重要.
相关概念视频
Insulin: Dosing Regimen and Adverse Effects
169
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
169
Diabetes: Management and Pharmacotherapy
277
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
277
Oral Hypoglycemic Agents: Biguanides and Glitazones
196
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
196
Diabetes Mellitus: Overview and Type I Subtype
2.6K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.6K
Oral Hypoglycemic Agents: Sulfonylureas
207
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
207
Diabetes Mellitus: Type 2 and Gestational
2.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.3K

